Showing results (1631-1640 of 5,935) with videos related to

Sort By:
Pageof 594
The Prostate|July 15, 2003
Familial aggregation of prostate cancer in African-Americans and white AmericansGlenn R Cunningham, Carol M Ashton, John F Annegers, et al.
The Prostate|July 15, 2003
Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8Andrea Kiessling, Susanne Füssel, Marc Schmitz, et al.
The Prostate|July 15, 2003
Mitogen-activated protein kinase pathway is involved in androgen-independent PSA gene expression in LNCaP cellsOmar E Franco, Takehisa Onishi, Kensuke Yamakawa, et al.
The Prostate|January 30, 2019
Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cellsShikha Gaur, Mitchell E Gross, Chun-Peng Liao, et al.
The Prostate|November 9, 2019
Disparities in prostate cancer incidence and mortality rates: Solvable or not?Simone Badal, William Aiken, Belinda Morrison, et al.
The Prostate|December 24, 2019
A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant ARF876L nuclear import and functionZeyu Wu, Ke Wang, Zhenyu Yang, et al.
The Prostate|December 10, 2019
Higher serum testosterone levels predict poor prognosis in castration-resistant prostate cancer patients treated with docetaxelKeisuke Ando, Shinichi Sakamoto, Nobushige Takeshita, et al.
The Prostate|January 17, 2020
Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?Jack R Andrews, Mohamed E Ahmed, R Jeffrey Karnes, et al.
The Prostate|January 23, 2020
Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activationHe Wenjing, Yuanyuan Shao, Yi Yu, et al.
The Prostate|January 24, 2020
Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancerMark C Markowski, Eugene Shenderov, Mario A Eisenberger, et al.
Pageof 594